CNTG News and Press, Centogene N.V. From 09/23/20

Centogene (CNTG): Q2 GAAP EPS of -€0.52.Revenue of €9.7M (-13.5% Y/Y)Shares +1% PM.Press Release For further details see: Centogene reports Q2 results

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that transforms real- world clinical and genetic data into actio...

Centogene (CNTG) +7% in premarket, after the company announced opening of a new COVID-19 testing facility at Düsseldorf Airport, and will provide its test solution to passengers departing from or arriving at Düsseldorf Airport, as well as to the general public.The res...

CENTOGENE expands its SARS-CoV-2 testing solution to Düsseldorf Airport after successfully launching walk-in COVID-19 test facilities at Frankfurt and Hamburg Airport Company’s PCR tests now available for passengers departing from or arriving at Düsseldorf Airport, as...

CAMBRIDGE, Mass., and ROSTOCK, Germany & BERLIN, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceu...

CENTOGENE has opened an expanded sampling area, next to the existing Walk-In COVID-19 Testing Facility, allowing significant increases in COVID-19 testing sampling capacity Innovative digital solutions continue to support the fight against the novel coronavirus with a customer-friendly te...

Publication demonstrates genome sequencing as the optimal standard for genetic testing Study presents the largest cohort of its kind with over 1,000 index cases Genome sequencing minimizes stepwise testing, thereby accelerating diagnosis for rare disease patients CAMBRIDGE, Mas...

CENTOGENE has recently opened coronavirus walk-in test centers at Frankfurt and Hamburg Airport, two of Germany’s largest airports Over 97% of COVID-19 test reports were processed within 24 hours in August 2020 – offering security and peace of mind to travelers The combinat...

Centogene (NASDAQ: CNTG ) and Evotec ( OTCPK:EVOTF ) have expanded their existing drug discovery partnership related to Gaucher disease – a genetic lysosomal storage disorder caused by mutations in the glucocerebrosidase gene. The parties intend to develop a treatment for Gauche...

CAMBRIDGE, Mass. and ROSTOCK, Germany and HAMBURG, Germany and BERLIN, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicia...